Reappraising neurotransmitter-based strategies

European Neuropsychopharmacology

Volumn 9, Issue SUPPL. 2, 1999, Pages

  Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acetylcholine deficit hypothesis; Acetylcholinesterase inhibitors; Alzheimer's disease; Cholinergic neurotransmission; Neurotransmitters

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; CONFERENCE PAPER; HUMAN; INFORMATION PROCESSING; NEUROTRANSMITTER RELEASE; PARASYMPATHETIC INNERVATION; PRIORITY JOURNAL; SENILE PLAQUE;

EID: 0345085628     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(98)00045-5     Document Type: Conference Paper

References (56)

1. Adolfsson R., Gottfries C.G., Roos B.E., Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br. J. Psychiatry. 135:1979;216-223.
2. Amaducci L., Crook T.H., Lippi A., Bracco L., Baldereschi M., Latorraca S., Piersanti P., Tesco G., Sorbi S. Use of phosphatidylserine in Alzheimer's disease. Ann. New York Acad. Sci. 640:1991;245-249.
3. Bierer L.M., Aisen P.S., Davidson M. A pilot study of oral physostigmine plus yohimbine in patients with AD. Alzheimer Dis. Assoc. Disord. 7:1993;98-104.
4. Bierer L.M., Aisen P.S., Davidson M., Ryan T.M., Schmeidler J., Davis K.L. A pilot study of clonidine plus physostigmine in AD. Dementia. 5:1994;243-246.
5. Bowen D.M., Benton J.S., Spillane J.A., Smith C.C., Allen S.J. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J. Neurol. Sci. 57:1982;191-202.
6. Candy, J.M., Fairburn, A.F., Johnson, M., 1986. Hippocampal cholinergic (muscarinic and putative nicotinic) receptors in human cognitive disorders. Proc. Brit. Pharm. Soc. Abstracts 88, (Suppl 35P).
7. Carlsson, A., 1981. Aging and brain neurotransmitters. In: Crook, T., Gershon, S. (Eds.), Strategies for the Development of an Effective Treatment for Senile Dementia. Mark Powley Associates, pp. 93-104.
8. Christensen H., Maltby N., Jorm A.F., Creasey H., Broe G.A. Cholinergic blockade as a model of the cognitive deficits in Alzheimer's disease. Brain. 115:1992;1681-1699.
9. Christie J.E., Shering A., Ferguson J., Glen A.I. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br. J. Psychiatry. 138:1981;46-50.
10. Cohen E.L., Wurtman R.J. Brain acetylcholine: increase after systemic choline administration. Life Sci. 16:1975;1095-1102.
11. Cooper, J.R., Bloom, F.E., Roth, R.H. (Eds.), 1996. The Biochemical Basis of Neuropharmacology. 7th ed. Oxford University Press, New York.
12. Cross A.J., Crow T.J., Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. BMJ (Clin. Res. Ed.). 282:1981;93-94.
13. Cross A.J., Crow T.J., Ferrier I.N., Johnson J.A., Bloom S.R., Corsellis J.A. Serotonin receptor changes in dementia of the Alzheimer type. J. Neurochem. 43:1984;1574-1581.
14. Cuadra G., Summers K., Giacobini E. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J. Pharmacol. Exp. Ther. 270:1994;277-284.
15. Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res. 171:1979;319-327.
16. Davies, P., 1981. Theoretical treatment possibilities for dementia of the Alzheimer type: the cholinergic hypothesis. In: Crook, T., Gershon, S. (Eds.), Strategies for the Development of an Effective Treatment for Senile Dementia. Mark Powley, New Canaan, pp. 19-32.
17. Davies P., Feisullin S. Postmortem stability of alpha-bungarotoxin binding sites in mouse and human brain. Brain Res. 216:1981;449-454.
18. Davis K.L., Hollister L.E., Overall J., Johnson A., Train K. Physostigmine: effects on cognition and affect in normal subjects. Psychopharmacology. 51:1976;23-27.
19. Drachman D.A., Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch. Neurol. 30:1974;113-121.
20. Farlow M., Gracon S.I., Hershey L.A., Lewis K.W., Sadowsky C.H., Dolan Ureno J. and the Tacrine Study Group, A controlled trial of tacrine in Alzheimer's disease. JAMA. 268:1992;2523-2529.
21. Fowler C.J., O'Neill C., Garlind A., Cowburn R.F. Alzheimer's disease: is there a problem beyond recognition? Trends Pharmacol. Sci. 11:1990;183-184.
22. Fowler C.J., O'Neill C., Winblad B., Cowburn R.F. Neurotransmitter, receptor and signal transduction disturbances in Alzheimer's disease. Acta Neurol. Scand. Suppl. 139:1992;59-62.
23. Gsell W., Strein I., Riederer P. The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J. Neural. Transm. Suppl. 47:1996;73-101.
24. Geula, C., Mesulam, M.-M., 1994. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry, R.D., Katzman, R., Bick, K.L., (Eds.), Alzheimer Disease, Raven Press, New York, pp. 263-291.
25. Hasselmo M.E., Anderson B.P., Bower J.M. Cholinergic modulation of cortical associative memory function. J. Neurophysiol. 67:1992;1230-1246.
26. Holttum J.R., Gershon S. The cholinergic model of dementia, Alzheimer type: progression from the unitary transmitter concept. Dementia. 3:1992;174-185.
27. Jones G.M., Sahakian B.J., Levy R., Warburton D.M., Gray J.A. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology. 108:1992;485-494.
28. Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I. and the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 271:1994;985-991.
29. Knopman D., Schneider L., Davis K., Talwalker S., Smith F., Hoover T., Gracon S. and the Tacrine Study Group. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology. 47:1996;166-177.
30. Kumar V., Calache M. Treatment of Alzheimer's disease with cholinergic drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. 29:1991;23-37.
31. Kurz A., Rüster P., Romero B., Zimmer R. Cholinerge Behandlungsstrategien bei der Alzheimerschen Krankheit. Nervenarzt. 57:1986;558-569.
32. Levy A., Brandeis R., Treves T.A., Meshulam Y., Mawassi F., Feiler D., Wengier A., Glikfeld P., Grunwald J., Dachir S., Rabey J.M., Levy D., Korezyn A.D. Transdermal physostigmine in the treatment of Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 8:1994;15-21.
33. Möller, H.-J., 1996. Acetylcholinmangelhypothese der Demenz und ihre klinisch-therapeutische Überprüfung. In: Möller H.-J., Möller-Spalim, F., Kurtz, G. (Eds.), Aktuelle Perspectivem der Biologischem Psychiatrie. Springer, Wien, New York, pp. 38-48.
34. Mori F., Lai C.C., Fusi F., Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport. 6:1995;633-636.
35. Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 258:1992;304-307.
36. Palmer A.M., Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 4:1990;2745-2752.
37. Perry E.K., Gibson P.H., Blessed G., Perry R.H., Tomlinson B.E. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci. 34:1977;247-265.
38. Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet. 1:1977;189.
39. Perry E.K., Tomlinson B.E., Blessed G., Bergmann K., Gibson P.H., Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 2:1978;1457-1459.
40. Potter, L.T., 1992. Strategies for the treatment of Alzheimer's disease: cholinergic agonists. In: Blass, J.P. and Khachaturian, Z.S. (Eds.), Alzheimer's Disease. Marcel Dekker, New York, pp. 57-66.
41. Reisine T.D., Yamamura H.I., Bird E.D., Spokes E., Enna S.J. Pre- and post-synaptic neurochemical alterations in Alzheimer's disease. Brain Res. 159(2):1978;477-481.
42. Rinne J.O., Rinne J.K., Laakso K., Paljarvi L., Rinne U.K. Reduction in muscarinic receptor binding in limbic areas of Alzheimer brain. J. Neurol. Neurosurg. Psychiatry. 47:1984;651-652.
43. Rogers S.L., Friedhoff S.T. and the Donepezil Study Group, The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 7:1996;293-303.
44. Rogers S.L., Farlow M.R., Doody R.S., Mohs R.C., Friedhoff L.T. and the Donepezil Study Group, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 50:1998;136-145.
45. Rusted J.M., Warburton D.M. Cognitive models and cholinergic drugs. Neuropsychobiology. 21:1989;31-36.
46. Sahakian B., Jones G., Levy R., Gray J., Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br. J. Psychiatry. 154:1989;797-800.
47. Sano M., Bell K., Marder K., Stricks L., Stern Y., Mayeux R. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease. Clin. Neuropharmacol. 16:1993;61-69.
48. Siegfried, K., Murphy, M.F., 1993. The cholinergic approach to the treatment of Alzheimer's disease. In: Wolters, E.C. and Scheltens, P. (Eds.), Alzheimer's Disease: Back to the Future. Vrije Universiteit, Amsterdam, pp. 97-106.
49. Sunderland T., Molchan S., Lawlor S.E. A strategy of 'combination chemotherapy' in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl. Int. Psychogeriatr. 2(4 Suppl):1992;291-309.
50. Warburton, D.M., 1990. Psychopharmacological aspects of nicotine. In: Wonnacott, S., Russell, M.A.H., Stolerman, I.P. (Eds.), Nicotine Psychopharmacology: Molecular, Cellular, and Behavioural aspects. Oxford University Press, Oxford, pp. 77-111.
51. Wenk G.L. The nucleus basalis magnocellularis cholinergic system: one hundred years of progress. Neurobiol. Learn. Mem. 67:1997;85-95.
52. White P., Hiley C.R., Goodhardt M.J., Carrasco L.H., Keet J.P., Williams I.E., Bowen D.M. Neocortical cholinergic neurons in elderly people. Lancet. 1:1977;668-671.
53. Whitehouse P.J. Cholinergic therapy in dementia. Acta Neurol. Scand. Suppl. 149:1993;42-45.
54. Whitehouse P.J., Struble R.G., Hedreen J.C., Clark A.W., Price D.L. Alzheimer's disease and related dementias: selective involvement of specific neuronal systems. CRC Crit. Rev. Clin. Neurobiol. 1:1985;319-339.
55. Wilcock G.K., Harrold P.L. Treatment of Alzheimer's disease: future directions. Acta Neurol. Scand. Suppl. 165:1996;128-136.
56. Winblad B., Messamore E., O'Neill C., Cowburn R. Biochemical pathology and treatment strategies in Alzheimer's disease: emphasis on the cholinergic system. Acta Neurol. Scand. Suppl. 149:1993;4-6.